Download PDF
CC BY-NC-ND 4.0 · Ann Natl Acad Med Sci 2018; 54(02): 090-095
DOI: 10.1055/s-0040-1712791
Original Article

Epidemiological Correlates and Treatment Outcomes among Patients with MDR Tuberculosis in Northern India

Anjana Singh
All India Institute of Medical Sciences, Rishikesh, Lucknow
,
Ved Prakash
King George's Medical University, Lucknow
,
Ravi Kant
King George's Medical University, Lucknow
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

ABSTRACT

Introduction: Multi drug resistant-TB (MDR-TB) threatens global TB control and is a major public health concern in several countries. The present study was undertaken to detect the epidemiological correlates and treatment outcomes among patients with MDR-TB previously or currently admitted in Department of Respiratory Medicine and Pulmonary and Critical Medicine, KGMU, Lucknow.

Material & Methods: This retrospective study included 2370 TB patients admitted in the Department of Respiratory Medicine and Pulmonary and Critical Medicine, KGMU, Lucknow between years 2012 to 2015. Treatment outcomes were observed. SPSS software was used for data analysis.

Results: The total number of MDR-TB cases enrolled were 2370. There were 772 (32.6%) males (95% CI: 30.7 % -34.5%) and 1598 (67.4%) females (95% CI: 65.5% -69.3%) registered for MDR-TB treatment. The treatment outcomes were as follows: majority (77.1%) were under treatment, 279 (11.8%) patients were declared cured, 10 (0.4%) were failure cases, while 64 (2.7%) were defaulters, 149 (6.3%) had died and 41(1.7%) were transferred out.

Conclusion: Emergence of MDR-TB has the potential to be a serious public health problem in Northern India and this necessitates strengthening of TB control and improved continuous monitoring of therapy.

Keywords:

MDR-TB - treatment outcome


Publication History

Article published online:
08 May 2020

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 World Health Organization. WHO/HTM/2018.13. Geneva: World Health Organization; 2018. Global Tuberculosis Report 2018.
  • 2 Chugh TD (2018). Human tuberculosis in India: some neglected issues. Curr Med Res Pract 8(2): 64-66.
  • 3 Subbaraman R, Nathavitharana RR, Satyanarayana S, et al (2016). The tuberculosis cascade of care in India's public sector: a systematic review and meta-analysis. PLoS Med 13: e1002149.
  • 4 Central TB Division, Directorate General of Health Services Ministry of Health and Family Welfare. TB Annual Report 2017. Nirman Bhavan, New Delhi: Central TB Division, Directorate General of Health Services Ministry of Health and Family Welfare; 2014. (Last accessed on 2018 Mar 18).
  • 5 Revised National Tuberculosis Control Programme. Technical and Operational Guidelines for Tuberculosis Control in India 2016.
  • 6 Alene KA, Hengzhong Yi, Viney K, et al (2017). Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China. BMC Infect Dis 17: 573.
  • 7 Udwadia ZF, Moharil G (2014). Multidrug-resistant-tuberculosis treatment in the Indian private sector: results from a tertiary referral private hospital in Mumbai. Lung India 31(4): 336–341.
  • 8 Khazaei S, Rezaeian S, Baigi V, et al (2017). Incidence and pattern of tuberculosis treatment success rates in different levels of the human development index: a global perspective. South Afr J Infect Dis 32(3): 100-104.
  • 9 Prasad R, Gupta N, Banka A (2017). Rapid diagnosis and shorter regimen for multidrug-resistant tuberculosis: a priority to improve treatment outcome. Lung India 34:1-2.
  • 10 Ibrahim E, Baess AI, Messery MAA (2017). Pattern of prevalence, risk factors and treatment outcomes among Egyptian patients with multidrug resistant tuberculosis. Egypt J Chest Dis Tuberc 66: 405–411.
  • 11 Moitra S, Sen S, Mukherjee S, Das P, Sinha S, Bose M (2015). Study of prevalence and outcome of standardized treatment on category I pulmonary tuberculosis cases in North India: A single center experience. Community Acquir Infect 2:83-92.
  • 12 Kumar A, Singh AK, Upadhyay V, Pandey J (2018). Epidemiology of multi-drugresistant tuberculosis in Northern India. Biomed Biotechnol Res J 2: 112-121.
  • 13 Dias HM, Pai M, Raviglione MC (2018). Ending tuberculosis in India: A political challenge & an opportunity. Indian J Med Res 147: 217-220.
  • 14 Singla R, Mallick M, Mrigpuri P, Singla N, Gupta A (2018). Sequelae of pulmonary multidrug-resistant tuberculosis at the completion of treatment. Lung India 35: 4-8.